Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | GSR | P00390 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | CLK1 | P49759 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6793634 | 0.75 | CHRNB2 (0.36) | CHRNB2CHRNA4SIGMAR1GSRNPC1 | |
| SCHEMBL6794364 | 0.75 | CHRNB2 (0.36) | CHRNB2CHRNA4SIGMAR1GSRNPC1 | |
| SCHEMBL6800060 | 0.75 | AURKA (0.46) | CHRNB2CHRNA4SIGMAR1GSRNPC1 | |
| SCHEMBL6792954 | 0.74 | NPC1 (0.44) | CHRNB2CHRNA4SIGMAR1GSRNPC1 | |
| SCHEMBL6787408 | 0.74 | MEN1 (0.58) | CHRNB2CHRNA4GSRNPC1RAB9A | |
| SCHEMBL6797114 | 0.73 | CCNA2 (0.58) | GSRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6793009 | 0.70 | NPC1 (0.39) | GSRNPC1KDM4EALPLHSD17B10 | |
| SCHEMBL6793663 | 0.70 | NPC1 (0.63) | GSRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6799055 | 0.69 | MEN1 (0.49) | GSRNPC1RAB9AMEN1KMT2A | |
| SCHEMBL6794908 | 0.68 | AURKA (0.54) | GSRNPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | CHRNB2 2820/4885CHRNA4 4133/4885SIGMAR1 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.